Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000686168 | SCV000813672 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2023-10-14 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 74 of the ALK protein (p.Pro74Leu). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with ALK-related conditions. ClinVar contains an entry for this variant (Variation ID: 566374). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Sema4, |
RCV002257926 | SCV002528418 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-05-07 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002257926 | SCV002729674 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-04-24 | criteria provided, single submitter | clinical testing | The p.P74L variant (also known as c.221C>T), located in coding exon 1 of the ALK gene, results from a C to T substitution at nucleotide position 221. The proline at codon 74 is replaced by leucine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV000686168 | SCV004197909 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2023-10-14 | criteria provided, single submitter | clinical testing |